In what is shaping up to be the largest overseas acquisition ever attempted by an Indian pharmaceutical company, Sun Pharma has laid a massive $13 billion all-cash offer on the table to buy US-based drugmaker Organon & Co.
The bold move signals a major strategic pivot for Sun Pharma. Spearheaded by Chairman Dilip Shanghvi, the company is actively pushing to expand beyond its traditional stronghold in generic medicines to secure a dominant position in the global specialty and innovative drug market.
The Anatomy of the Deal
This proposed buyout is strictly cash. Sun Pharma is not offering a share swap for Organon’s current shareholders. Instead, the deal is being heavily backed by a consortium of global lenders—including JPMorgan Chase, MUFG Bank, and Citigroup—who are financing roughly $12 billion of the transaction. Sun Pharma intends to use its own cash reserves to cover the rest.
If successful, Organon will be completely merged into Sun Pharma. However, a major hurdle in the transaction is Organon’s balance sheet. Since spinning off from Merck & Co. (MSD) in 2021, Organon has carried between $8 billion and $9 billion in debt, which Sun Pharma will have to absorb and refinance.
Why Organon?
Organon brings a highly specialized, established portfolio that Sun Pharma wants. The US company is a recognized leader in women’s health, producing vital treatments for breast cancer, osteoporosis, menopause, and contraception. Furthermore, Organon has a rapidly expanding and lucrative biosimilars business.
For Sun Pharma, acquiring these assets means gaining an immediate, massive commercial footprint in the US market, particularly in high-margin therapy areas that are difficult to build from the ground up.
A High-Stakes Bidding War
Sun Pharma does not appear to be alone in its desire to acquire Organon through a binding offer. This binding offer has ignited a competition amongst many buyers for Organon including Swedish private equity group EQT and German pharmaceutical company Grünenthal.
This fierce competition among buyers for Organon has created a dramatic impact on the entire marketplace as evidenced by the fact that Organon’s share price increased approximately thirty percent after the binding offer was made public.
The increase in Organon’s share price is occurring while Sun Pharma’s share price has experienced some modest downward pressure in India. Investors are aware, in the long term, of the financial opportunity for Sun Pharma buying Organon; however, in the short term there is a significant amount of financial risk due to Organon’s substantial debt level.
The Road Ahead
If Sun Pharma manages to outbid its European rivals, the acquisition will fundamentally reshape the company’s global standing. It sends a clear message that India’s top drugmakers are no longer content with just manufacturing affordable generics—they are ready to buy their way into the highest tiers of global pharmaceutical innovation.
